Last reviewed 2026-04-20 · How we verify

Albendazole 400 mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Pruritis / rash pruritic/ rash/ urticaria
• Malaria / complicated malaria
• Abdominal pain
• Itching
• Infections (various, not malaria)
• Hypertension
• Diarrhea
• Cough / Asthma
• Hypotension
• Abdominal pain and/or distension
• Myalgia / musculoskeletal stiffness

Key clinical trials

• Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
• Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (PHASE3)
• Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
• Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) (PHASE3)
• Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (PHASE3)
• Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
• Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (PHASE2)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Albendazole 400 mg CI brief — competitive landscape report
• Albendazole 400 mg updates RSS · CI watch RSS
• Jennifer Keiser portfolio CI